Eric Urhane
Angel Investor
Eric Urhane is a seed investor focused on Software and Health Care. Eric Urhane
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Eric Urhane invests in
Stages Eric Urhane invests in
Countries Eric Urhane invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.1M–$1.9M
Investment Focus
Industry
- Software 2 (40%)
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Cloud Computing 2 (40%)
- Health Diagnostics 2 (40%)
Stage
- Seed 3 (60%)
- Angel 2 (40%)
Country
- United States 3 (60%)
- Mexico 1 (20%)
- Singapore 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.9M / Seed / Mar 24, 2019 | ||
| X-ZELL is an award-winning medical technology company founded by Y Combinator alumnus, Dr Sebastian Bhakdi. We develop innovative laboratory solutions that enable same-day cancer diagnoses from minimally invasive sample material – we call it next-generation cytology (NGC). | $1.3M / Seed / Mar 22, 2016 | ||
| Chirply is a platform for crowd-sourcing & crowd-curating design. Chirply's mission is to build engagement, stickiness, and virality through crowd-sourcing design. Initially the company focused on the launch of a marketplace for crowd-sourced design for paper goods - an industry that hasn't been disrupted since the advent of theprinting press. Chirply then launched a B2B platform for crowd-sourced design for brands to help engage users and use design to make daily products inspiring. | $1.1M / Seed / Apr 07, 2011 | ||
| DotCloud is a 2nd-generation platform-as-a-service, and is the commercial entity behind Docker.io. Docker is an open source engine that makes it possible to pack, ship, and run any application as a lightweight container. | Angel / Feb 28, 2011 | ||
| Docker develops an open platform for building, shipping, and running distributed applications. Its platform allows developers and system administrators to create and run applications as a collection of containers that work across laptops, data center virtual machines, and public cloud instances. Docker also offers an application run-time andpackaging tool and a cloud service for sharing applications and automating workflows.Starting in 2008, dotCloud became Docker in October 2013, with its headquarters in San Francisco, California. | $800K / Angel / Feb 28, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eric Urhane invest in?
Eric Urhane invests primarily in Software, Health Care and Biotechnology startups, most often at Seed and Angel stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Eric Urhane invest in?
Eric Urhane typically joins rounds of $1.1M–$1.9M at Seed. These are whole funding-round sizes, not Eric Urhane's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Eric Urhane took part in.
How do I contact Eric Urhane?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eric Urhane last invest?
The most recent investment recorded for Eric Urhane closed in Mar 2019. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
